Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co., Inc. daily Stock Chart
Merck & Co., Inc.
IndexDJIA S&P500 P/E44.69 EPS (ttm)1.40 Insider Own0.04% Shs Outstand2.75B Perf Week0.10%
Market Cap172.14B Forward P/E14.99 EPS next Y4.18 Insider Trans-29.78% Shs Float2.74B Perf Month-0.78%
Income3.92B PEG7.01 EPS next Q0.84 Inst Own75.50% Short Float0.63% Perf Quarter3.39%
Sales39.81B P/S4.32 EPS this Y-10.00% Inst Trans0.12% Short Ratio1.92 Perf Half Y4.75%
Book/sh14.54 P/B4.31 EPS next Y10.05% ROA4.00% Target Price68.90 Perf Year15.32%
Cash/sh5.31 P/C11.81 EPS next 5Y6.37% ROE9.20% 52W Range51.48 - 66.32 Perf YTD7.27%
Dividend1.88 P/FCF47.32 EPS past 5Y-7.00% ROI6.20% 52W High-5.29% Beta0.86
Dividend %3.00% Quick Ratio1.50 Sales past 5Y-3.70% Gross Margin65.60% 52W Low22.02% ATR0.64
Employees68000 Current Ratio1.80 Sales Q/Q-1.00% Oper. Margin13.50% RSI (14)45.92 Volatility0.93% 0.90%
OptionableYes Debt/Eq0.62 EPS Q/Q-162.20% Profit Margin9.80% Rel Volume0.60 Prev Close62.70
ShortableYes LT Debt/Eq0.61 EarningsMay 02 BMO Payout130.00% Avg Volume8.99M Price62.81
Recom2.30 SMA20-0.12% SMA50-1.84% SMA2002.15% Volume1,170,860 Change0.18%
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Dec-19-16Downgrade Jefferies Hold → Underperform
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Apr-27-17 10:34AM  Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo Reuters
06:59AM  Bristol-Myers beats Wall St estimates, helped by Cancer drug Opdivo Reuters
Apr-26-17 05:08PM  Merck cholesterol drug Vytorin faces competition from Impax, Teva generics Reuters
04:12PM  FDA approves Impax generic of Merck's cholesterol drug Vytorin Reuters
11:13AM  What's in Store for Merck (MRK) this Earnings Season? Zacks
08:25AM  Short Sellers Cant Make Up Their Minds on Major Pharma 24/7 Wall St.
04:21AM  Moody's: Outlook for global pharmaceuticals industry stable on low earnings growth, new product launches Moody's
Apr-25-17 10:07PM  [$$] Aquinnah Pharmaceuticals Taps Pfizer, AbbVie for $10 Million The Wall Street Journal
01:00PM  Chill Pill: Eli Lilly Cuts Guidance with Earnings Investopedia
08:00AM  America's Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community PR Newswire
07:04AM  Better Buy: Celgene Corporation vs. Merck & Co., Inc. Motley Fool
Apr-24-17 02:32PM  Big Tech Is Taking on Diabetes Motley Fool
09:06AM  3 Key Factors to Look Out for in Biogen's Q1 Results Zacks
07:11AM  PDL BioPharma to be paid $19.5 million by Merck to settle Keytruda patent suit MarketWatch
Apr-22-17 07:00AM  Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C Business Wire
Apr-21-17 05:52PM  FDA approves 2nd near-copy of Remicade for immune disorders Associated Press
04:53PM  FDA approves near-copy of Remicade for immune disorders Associated Press
10:00AM  Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Mercks ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C Business Wire
08:08AM  10 Reasons Merck Could Be the World's Most Perfect Stock Motley Fool
Apr-20-17 09:30AM  The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria Zacks
09:00AM  Merck Donates $300,000 to Support Neglected Tropical Disease Elimination Efforts in Africa Business Wire
Apr-19-17 04:17PM  Is J&J's Pharma Sales Slowdown a Warning for Other Players? Zacks
03:47PM  Better Buy: Merck & Co. Inc. vs. Johnson & Johnson Motley Fool
08:00AM  Merck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017 Business Wire
Apr-18-17 02:07PM  Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem Business Wire
Apr-17-17 02:52PM  Is the market overvalued? CNBC Videos
Apr-13-17 06:01PM  Dow 30 Stock Roundup: Microsoft Buys Cloud Tech Firm, Disney's "Beauty and the Beast" Zacks
08:29AM  Bristol-Myers to license two drugs to Biogen, Roche Reuters
07:36AM  Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops Zacks
06:00AM  How US Drugmakers Profit From China's Biotech Boom Investopedia
Apr-12-17 11:46AM  Healthcare Sector Earnings: Making A Comeback In Q1 2017? Benzinga
Apr-11-17 04:23PM  Merck Stock History: The Drugmaker's Boom, Bust, and Bounce Back Motley Fool
11:09AM  Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma
Apr-10-17 04:30PM  Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors Business Wire
10:53AM  Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
10:36AM  Merck's Bid to Add Cardiovascular Data on Januvia Label Fails Zacks
Apr-09-17 03:03PM  The 3 Best HIV Drug Stocks to Buy in 2017 Motley Fool
Apr-07-17 03:05PM  Performance of Merck & Co. Stock in 1Q17 Market Realist
09:55AM  Dow Jones Industrial Average And Dow Stocks: News And Analysis Investor's Business Daily
09:28AM  FDA rejects Merck's bid to add heart data on diabetes drug labels Reuters
07:56AM  Merck receives FDA Complete Response Letter for medicines using sitagliptin MarketWatch
07:55AM  FDA rejects Merck's application to add heart safety data on diabetes drug labels Reuters
07:30AM  Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin Business Wire
Apr-06-17 10:00AM  Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency Business Wire
Apr-05-17 11:16AM  Merck & Co., Inc. : MRK-US: Dividend Analysis : March 15th, 2017 (record date) : By the numbers : April 5, 2017 Capital Cube
06:50AM  Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congress 2017 Business Wire
Apr-04-17 11:17AM  Incyte Is Smart to Date Around Bloomberg
10:49AM  Bristol-Myers Opdivo Fails In Glioblastoma Study Investopedia
Apr-03-17 11:40AM  Novocure Glioblastoma Drug Offers Survival Benefits Investopedia
09:06AM  How Eli Lillys Elanco Performed in 2016
08:31AM  For Bristol-Myers, A Victory And A Mystery Forbes
08:30AM  Bristol-Myers immunotherapy combination extends survival in melanoma Reuters
07:06AM  Kite Pharma Completes Filing for CAR-T Therapy with FDA
07:00AM  The cost of cancer: new drugs show success at a steep price Reuters
06:45AM  Merck to Hold First-Quarter 2017 Sales and Earnings Conference Call on May 2 Business Wire
02:00AM  The cost of cancer: new drugs show success at a steep price Reuters
Mar-31-17 03:30PM  Pharmaceutical giant Merck selects Austin for potential IT hub at
01:54PM  Austin to be Location of Merck IT Hub
12:48PM  Merck, Incyte Expand Cancer Collaboration at
12:21PM  Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?
10:35AM  Entresto Could See Strong Uptake in European Markets in 2017
07:00AM  Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab) Business Wire
Mar-30-17 10:36AM  Reduced Co-pays May Boost Demand for Entresto
09:06AM  What Could Boost Medicare Demand for Novartiss Entresto?
Mar-29-17 04:50PM  Eli Lillys Valuation Compared to Its Peers
04:01PM  VBI Vaccines Emerges as Strong Biotech Stock
07:36AM  What Wall Street Analysts Recommend for Merck
05:40AM  UPDATE 2-Roche MS drug Ocrevus approved by FDA after 3-month delay Reuters
Mar-28-17 06:05PM  Will Novartis See Rise in Net Profit Margins in 2017?
12:18PM  Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer
10:37AM  How Mercks Animal Health Segment Performed in 2016
09:06AM  This Is Driving Mercks Vaccines Business
07:36AM  How Decline in Remicade Is Affecting Mercks Immunology Revenues
Mar-27-17 03:53PM  10 Biggest Recent Accounting Scandals in America at Insider Monkey
09:08AM  Mercks Keytruda Saw Impressive Growth in 2016
09:07AM  Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma
Mar-26-17 09:03AM  3 Tremendously Promising Diabetes Drugs Potentially on the Way at Motley Fool
Mar-24-17 04:51PM  Trump, Ryan Spike Health Care Vote in Setback for President, GOP
04:16PM  How Does Mercks Valuation Compare to Peers?
01:31PM  Merck Keytruda Gets CHMP Nod for Hodgkin's Lymphoma at Investopedia
01:14PM  [$$] Merck wins approval for skin cancer treatment at Financial Times
12:58PM  Healthcare: Will They or Won't They? at
09:58AM  Merck Is Dangerously Close to a Breakdown
08:13AM  European Medicines Agencys CHMP Recommends Approval of Mercks KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Business Wire
06:46AM  Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment
05:50AM  Pfizer, Merck KGaA Get FDA Nod for Skin Cancer Drug (PFE) at Investopedia
03:40AM  Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month
Mar-23-17 10:00AM  Merck Closes Acquisition of Controlling Stake in Vallee S.A
08:59AM  The Supreme Court could fundamentally change America's broken patent system
Mar-22-17 04:05PM  Merck Animal Health Completes Acquisition of Vallée S.A. Business Wire
12:24PM  Merck must face renewed Fosamax warning claims -U.S. appeals court Reuters
11:47AM  Merck Osteoporosis Drug Linked to Thigh Fractures at Investopedia
10:37AM  Durvalumab and Tagrisso May Boost AstraZenecas Revenues in 2017
08:48AM  U.S. appeals court revives Fosamax warning claims against Merck
Mar-21-17 06:05PM  Japan May Prove to Be Strong Growth Driver for AstraZeneca in 2017
09:30AM  The Zacks Analyst Blog Highlights: Merck, General Electric, MasterCard and NVIDIA
Mar-20-17 04:10PM  Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal
10:06AM  Why Biotech Stock Gilead (GILD) Could Be a Value Trap
09:41AM  Pfizer, Merck KGaA Delay Lung Cancer Drug Trial Outcome at Investopedia
Mar-17-17 09:27AM  Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schechter Adam HEVP & Pres-Global Human HealthApr 03Sale63.4853,8503,418,166116,336Apr 04 06:36 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale64.732,954191,22711,675Feb 15 11:30 AM
RUSSO PATRICIA FDirectorFeb 08Option Exercise35.195,000175,95018,148Feb 09 12:52 PM
RUSSO PATRICIA FDirectorFeb 08Sale64.425,000322,12113,148Feb 09 12:52 PM
WEEKS WENDELL PDirectorFeb 06Option Exercise51.865,000259,3005,100Feb 06 03:35 PM
WEEKS WENDELL PDirectorFeb 06Sale64.515,000322,542100Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Option Exercise32.5115,000487,65016,000Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Option Exercise59.0977,9594,606,471142,239Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Option Exercise34.3536,3351,248,17336,335Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Option Exercise35.195,000175,9505,100Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Sale63.425,000317,100100Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Sale63.7336,3352,315,6990Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Sale63.9691,9595,881,25250,280Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Sale63.6915,000955,4061,000Feb 06 03:35 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise23.45133,9203,140,424642,797Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale65.03133,9208,709,286508,877Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Option Exercise23.456,080142,576514,957Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale65.006,080395,200508,877Nov 10 05:29 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise41.5385,5233,551,946124,638Nov 08 11:51 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale60.0285,5235,133,33039,115Nov 08 11:51 AM
LAZARUS ROCHELLE BDirectorNov 02Option Exercise37.3520,000746,95024,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Option Exercise51.865,000259,3006,000Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Sale59.505,000297,5001,000Nov 02 04:54 PM
LAZARUS ROCHELLE BDirectorNov 02Sale59.0620,0001,181,2004,594Nov 02 04:54 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Option Exercise44.1940,8001,802,952128,973Oct 04 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Sale62.0740,8002,532,58288,173Oct 04 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Option Exercise33.4939,2001,312,80839,200Sep 01 03:37 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Sale62.6139,2002,454,3080Sep 01 03:37 PM
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM